May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Triple Therapy in Retinal Venous Occlusion
Author Affiliations & Notes
  • A. Seener
    Ophthalmology, Artemis-Eyer-Clinics, Dillenburg, Germany
  • F. Al-Sarireh
    Department of Ophthalmology, Vitreo-Retinal Surgery, Johann-Wolfgang Goethe University Frankfurt/Main, Germany
  • S. Scholtz
    Department of Ophthalmology, Vitreo-Retinal Surgery, Johann-Wolfgang Goethe University Frankfurt/Main, Germany
  • P. Singh
    Department of Ophthalmology, Vitreo-Retinal Surgery, Johann-Wolfgang Goethe University Frankfurt/Main, Germany
  • M. J. Koss
    Department of Ophthalmology, Vitreo-Retinal Surgery, Johann-Wolfgang Goethe University Frankfurt/Main, Germany
  • F. H. Koch
    Department of Ophthalmology, Vitreo-Retinal Surgery, Johann-Wolfgang Goethe University Frankfurt/Main, Germany
  • Footnotes
    Commercial Relationships  A. Seener, None; F. Al-Sarireh, None; S. Scholtz, None; P. Singh, None; M.J. Koss, None; F.H. Koch, INTRECTOR InsightInstruments, P.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4690. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Seener, F. Al-Sarireh, S. Scholtz, P. Singh, M. J. Koss, F. H. Koch; Triple Therapy in Retinal Venous Occlusion. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4690. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report the effect of a triple therapy (TT= core pars plana vitrectomy(cppV), intravitreal triamcinolone and bevacizumab injection) for the treatment of macular edema secondary to central (CRVO) and branch retinal vein occlusion(BRVO).

Methods: : Retrospective case series of 57 patients (mean age 70), divided in ischemic CRVO(n=16,group I); non-ischemic CRVO(n=12,group II) and BRVO(n=29,group III).All groups received a 23 gauge cppV (sutureless, single sclerotomy) with aspiration of 0.5ml vitreous and substitution of 0.8 mg triamcinolone and 1.25mg bevacizumab through two different openings in one probe tip. Main outcome measures included BCVA(5m Snellen), IOP, OCT and fluorescein angiography.

Results: : F/u was 12 and 24 weeks post surgery. BCVA improved from 0.02 to 0.06 (group I), 0.15 to 0.37(group II), 0.25 to 0.48 (group III). All patients, except of 4/13 (30,8% in group I) showed significant macular edema resolution. IOP rise was measured in 3/50 cases (6%). TT was continued in 10/50 cases (20%); laserphotocoagulation was conducted in 8/50 cases (16%) 6 months after TT.

Conclusions: : TT indicates promising prelimary results concerning VA and ME resolution in non-ischemic RVO mainly, which could be enhanced by a intravasal lysis with venous catherization to increase the redistribution of intraocular oxygen already induced by the core vitrectomy.

Keywords: vascular occlusion/vascular occlusive disease • edema • oxygen 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×